{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:10:34Z","timestamp":1768558234693,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":434,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title\/><jats:p>Melanoma can be classified based on the detection of relevant oncogenic driver mutations. These mutations partially determine a patient's treatment options. MEK inhibitors have demonstrated little efficacy in patients with NRAS-mutated melanoma owing to primary and secondary resistance. We report two patients with NRAS-mutant metastatic melanoma with long-term response to intermittent MEK-inhibitor binimetinib therapy. Intermittent dosing schedules could play a key role in preventing resistance to targeted therapy. This article highlights the efficacy of an intermittent dosing schedule, toxicities associated with binimetinib, and possible mechanisms preventing resistance in targeted therapy. Intermittent MEK-inhibitor therapy may be considered in patients with NRAS-mutated melanoma that have failed all standard therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Points<\/jats:title><jats:p>Melanomas harbor NRAS mutations in 10%\u201330% of the cases. These mutations promote hyperactivation of the MAPK pathway, leading to proliferation and prolonged survival of tumor cells. Currently, drugs directly targeting NRAS are not available. Downstream inhibition of the MAPK pathway can be considered as a therapeutic option after immunotherapeutic failure. Intermittent administration of kinase inhibitors might be the way to partially overcome the development of drug resistance by (a) inducing a fitness deficit for drug-resistant cells on treatment break, (b) increasing the immunogenicity, and (c) inducing apoptosis and cell cycle arrest. It also enhances expression of numerous immunomodulating molecules, and reduction of immunosuppressive factors, which suggests better access of the immune system to the tumor.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0656","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T15:59:40Z","timestamp":1600703980000},"page":"e1593-e1597","source":"Crossref","is-referenced-by-count":15,"title":["Long-Term Response to Intermittent Binimetinib in Patients with<i>NRAS<\/i>-Mutant Melanoma"],"prefix":"10.1093","volume":"25","author":[{"given":"Alexandra Valeska","family":"Matter","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Micaletto","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Urner-Bloch","sequence":"additional","affiliation":[{"name":"Department of Private Ophthalmic Practice in Cooperation with the Skin Cancer Unit, University Hospital of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland"},{"name":"Faculty of Medicine, University of Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"2021122511251750200_onco13512-bib-0001","first-page":"163","article-title":"Melanoma development: Current knowledge on melanoma pathogenesis","volume":"27","author":"Lugovic-Mihic","year":"2019","journal-title":"Acta Dermatovenerol Croat"},{"key":"2021122511251750200_onco13512-bib-0002","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"2021122511251750200_onco13512-bib-0003","doi-asserted-by":"crossref","first-page":"77163","DOI":"10.18632\/oncotarget.12848","article-title":"Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance","volume":"7","author":"Raaijmakers","year":"2016","journal-title":"Oncotarget"},{"key":"2021122511251750200_onco13512-bib-0004","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.2147\/DDDT.S131721","article-title":"MEK inhibitors for the treatment of NRAS mutant melanoma","volume":"12","author":"Sarkisian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"2021122511251750200_onco13512-bib-0005","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/onc.2012.453","article-title":"NRAS mutant melanoma: Biological behavior and future strategies for therapeutic management","volume":"32","author":"Fedorenko","year":"2013","journal-title":"Oncogene"},{"key":"2021122511251750200_onco13512-bib-0006","doi-asserted-by":"crossref","first-page":"Re13","DOI":"10.1126\/stke.2502004re13","article-title":"Human RAS superfamily proteins and related GTPases","volume":"2004","author":"Colicelli","year":"2004","journal-title":"Sci STKE"},{"key":"2021122511251750200_onco13512-bib-0007","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1002\/cncr.30593","article-title":"Somatic driver mutations in melanoma","volume":"123","author":"Reddy","year":"2017","journal-title":"Cancer"},{"key":"2021122511251750200_onco13512-bib-0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122511251750200_onco13512-bib-0009","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021122511251750200_onco13512-bib-0010","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511251750200_onco13512-bib-0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00038","article-title":"Intermittent treatment with MEK inhibitors in patients with oncogenic RAF-driven tumors: A potential strategy to manage toxicity and maintain efficacy","volume":"2","author":"Yaeger","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2021122511251750200_onco13512-bib-0012","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.30435","article-title":"Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma","volume":"123","author":"Lim","year":"2017","journal-title":"Cancer"},{"key":"2021122511251750200_onco13512-bib-0013","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature11814","article-title":"Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance","volume":"494","author":"Das Thakur","year":"2013","journal-title":"Nature"},{"key":"2021122511251750200_onco13512-bib-0014","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1074\/jbc.M308644200","article-title":"High intensity RAS signaling induces premature senescence by activating p38 pathway in primary human fibroblasts","volume":"279","author":"Deng","year":"2004","journal-title":"J Biol Chem"},{"key":"2021122511251750200_onco13512-bib-0015","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/0008-5472.CAN-13-1633","article-title":"The evolution of melanoma resistance reveals therapeutic opportunities","volume":"73","author":"Das Thakur","year":"2013","journal-title":"Cancer Res"},{"key":"2021122511251750200_onco13512-bib-0016","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pcmr.12370","article-title":"Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy","volume":"28","author":"Wellbrock","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021122511251750200_onco13512-bib-0017","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021122511251750200_onco13512-bib-0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1755-148X.2010.00823.x","article-title":"A proliferative melanoma cell phenotype is responsive to RAF\/MEK inhibition independent of BRAF mutation status","volume":"24","author":"Zipser","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021122511251750200_onco13512-bib-0019","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1238557","article-title":"Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma","volume":"5","author":"Deken","year":"2016","journal-title":"Oncoimmunology"},{"key":"2021122511251750200_onco13512-bib-0020","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"Map kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"2021122511251750200_onco13512-bib-0021","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1335843","article-title":"MEK inhibition and immune responses in advanced melanoma","volume":"6","author":"Dummer","year":"2017","journal-title":"Oncoimmunology"},{"key":"2021122511251750200_onco13512-bib-0022","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.celrep.2019.03.066","article-title":"Pulsatile MEK inhibition improves anti-tumor immunity and T cell function in murine KRAS mutant lung cancer","volume":"27","author":"Choi","year":"2019","journal-title":"Cell Rep"},{"key":"2021122511251750200_onco13512-bib-0023","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.066","article-title":"LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (WT) advanced melanoma: Primary analysis from the phase III IMspire170 trial","volume":"30","author":"Arance","year":"2019","journal-title":"Ann Oncol"},{"key":"2021122511251750200_onco13512-bib-0024","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/2159-8290.CD-17-0699","article-title":"In vivo E2F reporting reveals efficacious schedules of MEK1\/2-CDK4\/6 targeting and mTOR-S6 resistance mechanisms","volume":"8","author":"Teh","year":"2018","journal-title":"Cancer Discov"},{"key":"2021122511251750200_onco13512-bib-0025","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1038\/ncomms7051","article-title":"The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors","volume":"6","author":"Zingg","year":"2015","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0656","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/e1593\/41920630\/oncolo_25_11_e1593.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/e1593\/41920630\/oncolo_25_11_e1593.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T07:21:27Z","timestamp":1723620087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/11\/e1593\/6443227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,9,21]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0656","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,9,21]]}}}